Usefulness of Quinapril and Irbesartan to improve the anti-inflammatory response of Atorvastatin and Aspirin in patients with coronary heart disease

American Journal of Cardiology

Volumn 91, Issue 9, 2003, Pages 1116-1119

  Lauten, Wright B ^b   Khan, Qamar A ^b   Rajagopalan, Sanjay ^b   Lerakis, Stamatios ^b   Rahman, Syed T ^b   Parthasarathy, Sampath ^b   Khan, Bobby V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD11B ANTIGEN; CREATININE; INTERLEUKIN 6; IRBESARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; POTASSIUM; QUINAPRIL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANAMNESIS; ANGIONEUROTIC EDEMA; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; COUGHING; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEART EJECTION FRACTION; HEART INFARCTION; HEMODYNAMICS; HUMAN; HYPOTENSION; IMMUNOLOGICAL PROCEDURES; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PATIENT SELECTION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 0344942643     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00161-9     Document Type: Article

References (10)

1. Lonn E.M., Yosuf S., Jha P., Montague T.J., Teo K.K., Benedict C.R., Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90:1994;2056-2069.
2. Pfeffer M.A. Enhancing cardiac protection after myocardial infarction rationale for newer clinical trials of angiotensin receptor blockers . Am Heart J. 139:2000;S23-28.
3. Rajagopalan S., Harrison D.G. Reversing endothelial dysfunction with angiotensin-converting enzyme inhibitors. A new trend? Circulation. 94:1996;240-243.
4. Porsch-Oezcueruemez M., Kunz D., Kloer H., Luley C. Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease. J Am Coll Cardiol. 34:1999;1995-2001.
5. Strawn W.B., Chappell M.C., Dean R.H., Kivlighn S., Ferrario C.M. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 101:2000;1586-1593.
6. Kaplan N.M. Maximally reducing cardiovascular risk in the treatment of hypertension. Ann Intern Med. 109:1988;36-40.
7. Effects of an angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 342:2000;145-153.
8. Lonn E., Yusuf S., Dzavik V., Doris C., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W., Teo K. Effects of ramipril and vitamin E on atherosclerosis the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE) . Circulation. 103:2001;919-925.
9. 1 receptor antagonist, reduces markers of inflammation in patients with early atherosclerosis. J Am Coll Cardiol. 37:2001;440-444.
10. Khan B.V., Navalkar S., Khan Q.A., Rahman S.T., Parthasarathy S. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J Am Coll Cardiol. 38:2001;1662-1667.